Evolution of sinonasal clinical features in children with cystic fibrosis.

P Suy, A Coudert, S Vrielynck, E Truy, R Hermann, S Ayari-Khalfallah

Journal: International journal of pediatric otorhinolaryngology 2019;124():47-53

PMID: 31158571

Abstract

OBJECTIVE

to assess the evolution of sinonasal manifestations in children with cystic fibrosis, since the improvement of their prognosis over the last decades.

METHODS

an observational, monocentric study with a retrospective cohort. We included 173 children (from 4 to 18 years old) with cystic fibrosis followed at the pediatric cystic fibrosis center of lyon, france. We collected respiratory, infectious and nutritional data, sinonasal complaints and physical examination at the onset of sinonasal symptoms (t-0), at the most severe of evolution (t-max) and at the end of followup (t-end).

RESULTS

sinonasal symptomatology appeared early around 5.4 years old, then rapidly reached the maximum at 6.9 years and finally improved during childhood (p < 0.0001), reaching scores at t-end significantly better than at t-0 (p < 0.0001). This evolution was significant for nasal obstruction, rhinorrhea and snoring. The other symptoms were rarer, with no significant 38,7% at t-max (p < 0.0001), and 29,5% at t-end (p = 0.52). The lildholdt score, turbinate hypertrophy and medial bulging of medial wall of the maxillary sinus followed the same evolution (p < 0.003). There was no association between sinonasal evolution and cystic fibrosis disease at infectious, respiratory or nutritional level.

CONCLUSION

it is the only recent study evaluating the evolution of each sinonasal manifestations in children with cystic fibrosis. Rhinosinusitis improved during childhood, reaching better scores than at the beginning of management. This particular improvement may be related to good effectiveness to ent management, but also to a positive effect of nasal cavity growth, independently to extra-ent manifestations.

Copyright © 2019 Elsevier B.V. All rights reserved.

Address: Service d'ORL pédiatrique, Hôpital femme Mère Enfants, Centre Hospitalier et Universitaire Lyon, France; Service d'ORL, Hôpital Edouard Herriot, Centre Hospitalier et Universitaire Lyon, France. Electronic address: [email protected].; Service d'ORL pédiatrique, Hôpital femme Mère Enfants, Centre Hospitalier et Universitaire Lyon, France; Université de Lyon, Lyon, France; INSERM, U1028, CNRS, UMR5292, Lyon Neuroscience Research Center, IMPACT Team, Lyon, France. Electronic address: [email protected].; Service de Pneumologie, Hôpital de Ghiens, France. Electronic address: [email protected].; Service d'ORL pédiatrique, Hôpital femme Mère Enfants, Centre Hospitalier et Universitaire Lyon, France; Service d'ORL, Hôpital Edouard Herriot, Centre Hospitalier et Universitaire Lyon, France; Université de Lyon, Lyon, France; INSERM, U1028, CNRS, UMR5292, Lyon Neuroscience Research Center, IMPACT Team, Lyon, France. Electronic address: [email protected].; Service d'ORL, Hôpital Edouard Herriot, Centre Hospitalier et Universitaire Lyon, France; Université de Lyon, Lyon, France; INSERM, U1028, CNRS, UMR5292, Lyon Neuroscience Research Center, IMPACT Team, Lyon, France. Electronic address: [email protected].; Service d'ORL pédiatrique, Hôpital femme Mère Enfants, Centre Hospitalier et Universitaire Lyon, France; Service d'ORL, Hôpital Edouard Herriot, Centre Hospitalier et Universitaire Lyon, France. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.